CTLA4 and cancer: The development of immune checkpoint inhibitors, especially monoclonal antibodies that target vital proteins like programmed death receptor 1 (PD-1) and cytotoxic lymphocyte-associated protein 4 (CTLA-4), has revolutionized the treatment of cancer.